Back to Screener

TriSalus Life Sciences, Inc. Warrant (TLSIW)

Price$0.98

Favorite Metrics

Price vs S&P 500 (26W)-27.93%
Price vs S&P 500 (4W)-26.48%

All Metrics

Price vs S&P 500 (YTD)-42.99%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.00M
52-Week High$5.00
26-Week Price Return-24.15%
13-Week Price Return-5.00%
3-Month Return Std Dev216.14%
Year-to-Date Return-41.05%
5-Day Price Return-17.77%
Month-to-Date Return-18.46%
Price vs S&P 500 (13W)-5.06%
Beta2.04x
52-Week Low$0.42

Industry Peers — Surgical & Medical Instruments(109)

SymbolP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
TLSIWTriSalus Life Sciences, Inc. Warrant
$0.98
SYKStryker Corporation
5.15x11.84%64.57%19.43%$338.38
BSXBoston Scientific Corp.
4.76x15.16%69.01%18.00%$63.42
MMM3M Company
3.18x-4.97%39.92%18.55%$150.55
MDLNMedline Inc. Class A common stock
2.21x26.44%7.78%$46.94
BDXBecton, Dickinson and Co.
2.01x6.32%46.42%12.15%$154.82
RMDResMed Inc.
6.06x11.72%60.85%33.70%$224.72
DXCMDexCom, Inc.
5.23x19.33%62.09%19.56%$61.23
WSTWest Pharmaceutical Services, Inc.
6.22x7.44%35.91%19.03%$269.81
PODDInsulet Corporation
5.31x24.53%71.63%12.92%$201.47
PENPenumbra, Inc.
9.31x20.16%67.14%13.48%$331.47

About

TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics targeting difficult-to-treat liver and pancreatic cancers. The company markets PEDD (Pressure Enabled Drug Delivery) infusion systems, including its latest TriNav device with SmartValve technology, which are in clinical use today. It is also advancing nelitolimod (SD-101), an investigational agent designed to enhance immune response against hepatocellular carcinoma, pancreatic cancer, and other liver tumors.